Conjugated Monoclonal Antibodies Global Market Report 2023

Description

“Conjugated Monoclonal Antibodies Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugated monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugated monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The conjugated monoclonal antibodies market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drugs: Adcetris; Kadcyla

2) By Technology: Cleavable Linker; Non-cleavable Linker

3) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumour; Other Applications

Companies Mentioned: Pfizer Inc.; F. Hoffmann-LA; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the conjugated monoclonal antibodies market are: Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc.

The global conjugated monoclonal antibodies market is expected to grow from $8.89 billion in 2021 to $9.64 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The conjugated monoclonal antibodies market is expected to reach $12.09 billion in 2026 at a CAGR of 5.8%.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Conjugated monoclonal antibodies refer to a compound formed of a monoclonal antibody that has been chemically coupled to a medication. The monoclonal antibody binds to particular proteins or receptors that are present on particular cell types, such as cancer cells. The associated medicine enters these cells, kills them, and leaves the rest of the cells alone.

North America was the largest region in the conjugated monoclonal antibodies market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of drugs in conjugated monoclonal antibodies are advertised and kadcyla. Adcetris is a brand-name pharmaceutical drug intended to cure adults with certain types of lymphoma. Lymphoma is cancer that attacks the lymphatic system and lymphocytes, which are white blood cells. The different technologies include cleavable linkers, and non-cleavable linkers and are used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, and others.

The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), are a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs till last 3-4 years, it has approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer which in turn aids in the growth of the market.

The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the cost of the first FDA-approved radioimmunotherapy drug Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas which was approved in December 2019 costs between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries which hinders the growth of the conjugated monoclonal antibodies market.

Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market. For instance, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar's MNPR-101 a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells.

In July 2020, AstraZeneca, a UK-based drugmaker entered into a partnership with Daiichi Sankyo for an amount of $6 billion. This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC) which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumor cells. Daiichi Sankyo is a Japanese-based pharmaceutical company engaged in the development of antibody-drug conjugates.

The countries covered in the conjugated monoclonal antibodies market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The conjugated monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market statistics, including conjugated monoclonal antibodies industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. This conjugated monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2032

1. Executive Summary

2. Conjugated Monoclonal Antibodies Market Characteristics

3. Conjugated Monoclonal Antibodies Market Trends And Strategies

4. Conjugated Monoclonal Antibodies Market - Macro Economic Scenario

4.1 COVID-19 Impact On Conjugated Monoclonal Antibodies Market

4.2 Ukraine-Russia War Impact On Conjugated Monoclonal Antibodies Market

4.3 Impact Of High Inflation On Conjugated Monoclonal Antibodies Market

5. Conjugated Monoclonal Antibodies Market Size And Growth

5.1. Global Conjugated Monoclonal Antibodies Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global Conjugated Monoclonal Antibodies Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. Conjugated Monoclonal Antibodies Market Segmentation

6.1. Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Adcetris
Kadcyla
6.2. Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Cleavable Linker
Non-cleavable Linker
6.3. Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumour
Other Applications

7. Conjugated Monoclonal Antibodies Market Regional And Country Analysis

7.1. Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Conjugated Monoclonal Antibodies Market

8.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Conjugated Monoclonal Antibodies Market

9.1. China Conjugated Monoclonal Antibodies Market Overview
9.2. China Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Conjugated Monoclonal Antibodies Market

10.1. India Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Conjugated Monoclonal Antibodies Market

11.1. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Conjugated Monoclonal Antibodies Market

12.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Conjugated Monoclonal Antibodies Market

13.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Conjugated Monoclonal Antibodies Market

14.1. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Conjugated Monoclonal Antibodies Market

15.1. Western Europe Conjugated Monoclonal Antibodies Market Overview
15.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Conjugated Monoclonal Antibodies Market

16.1. UK Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Conjugated Monoclonal Antibodies Market

17.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Conjugated Monoclonal Antibodies Market

18.1. France Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Conjugated Monoclonal Antibodies Market

19.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview
19.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Conjugated Monoclonal Antibodies Market

20.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Conjugated Monoclonal Antibodies Market

21.1. North America Conjugated Monoclonal Antibodies Market Overview
21.2. North America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Conjugated Monoclonal Antibodies Market

22.1. USA Conjugated Monoclonal Antibodies Market Overview
22.2. USA Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Conjugated Monoclonal Antibodies Market

23.1. South America Conjugated Monoclonal Antibodies Market Overview
23.2. South America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Conjugated Monoclonal Antibodies Market

24.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Conjugated Monoclonal Antibodies Market

25.1. Middle East Conjugated Monoclonal Antibodies Market Overview
25.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Conjugated Monoclonal Antibodies Market

26.1. Africa Conjugated Monoclonal Antibodies Market Overview
26.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Conjugated Monoclonal Antibodies Market Competitive Landscape And Company Profiles

27.1. Conjugated Monoclonal Antibodies Market Competitive Landscape
27.2. Conjugated Monoclonal Antibodies Market Company Profiles
- 27.2.1. Pfizer Inc.
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. F. Hoffmann-LA
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Bristol -Myers Squibb
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Merck & Co. Inc.
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. Immunomedics Inc.
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Conjugated Monoclonal Antibodies Pipeline Analysis

29. Key Mergers And Acquisitions In The Conjugated Monoclonal Antibodies Market

30. Conjugated Monoclonal Antibodies Market Future Outlook and Potential Analysis

31. Appendix

31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. The Business Research Company
31.6. Copyright And Disclaimer